Tenax Therapeutics Inc (TENX) posted a Q4 2025 GAAP loss of $0.38 per share, wider than $0.18 per share loss reported last year, but beat estimates. The clinical-stage pharmaceutical company develops novel cardiopulmonary therapies in the United States.
Tenax is advancing its pipeline of levosimendan formulations (TNX-101, TNX-102, and TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction, which have completed phase II clinical trials. The company also develops TNX-201 (imatinib), a tyrosine kinase inhibitor for chronic myeloid leukemia treatment.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Tenax Therapeutics Inc (TENX) Q4 Loss Widens, But Beats Estimates first appeared on Alphastreet.
